BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32442855)

  • 1. Somatostatin receptor-2 negative meningioma: pathologic correlation and imaging implications.
    Roytman M; Pisapia DJ; Liechty B; Lin E; Skafida M; Magge RS; Osborne JR; Pannullo SC; Knisely JPS; Ramakrishna R; Ivanidze J
    Clin Imaging; 2020 Oct; 66():18-22. PubMed ID: 32442855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.
    Rachinger W; Stoecklein VM; Terpolilli NA; Haug AR; Ertl L; Pöschl J; Schüller U; Schichor C; Thon N; Tonn JC
    J Nucl Med; 2015 Mar; 56(3):347-53. PubMed ID: 25635133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma.
    Wang S; Yang W; Deng J; Zhang J; Ma F; Wang J
    J Neurooncol; 2013 Jul; 113(3):519-26. PubMed ID: 23657621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma.
    Kurz SC; Zan E; Cordova C; Troxel AB; Barbaro M; Silverman JS; Snuderl M; Zagzag D; Kondziolka D; Golfinos JG; Chi AS; Sulman EP
    Clin Cancer Res; 2024 Feb; 30(4):680-686. PubMed ID: 38048045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas.
    Ivanidze J; Roytman M; Lin E; Magge RS; Pisapia DJ; Liechty B; Karakatsanis N; Ramakrishna R; Knisely J; Schwartz TH; Osborne JR; Pannullo SC
    J Neuroimaging; 2019 Sep; 29(5):650-656. PubMed ID: 31107591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pearls and Pitfalls in Interpretation of 68Ga-DOTATOC PET Imaging.
    Bashir A; Broholm H; Clasen-Linde E; Vestergaard MB; Law I
    Clin Nucl Med; 2020 Jun; 45(6):e279-e280. PubMed ID: 32332303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.
    Boursier C; Zaragori T; Bros M; Bordonne M; Melki S; Taillandier L; Blonski M; Roch V; Marie PY; Karcher G; Imbert L; Verger A
    Eur Radiol; 2023 Oct; 33(10):7089-7098. PubMed ID: 37148355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor-positive granulomatous inflammation mimicking as meningioma on simultaneous PET/MRI.
    Taneja S; Jena A; Kaul S; Jha A; Sogani SK
    Clin Nucl Med; 2015 Jan; 40(1):e71-2. PubMed ID: 24662657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B; Asopa R; Basu S
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary Molecular and Metabolic Characterization of Meningiomas With DOTATATE and FDG-PET: Advancing Treatment Planning and Prognostication.
    Dressen MS; Muthukrishnan A; Tragon TR; Lieberman FS; Mountz JM
    Clin Nucl Med; 2019 Jan; 44(1):e26-e27. PubMed ID: 30371576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biologic and scintigraphic analyses of somatostatin receptor-negative meningiomas.
    Meewes C; Bohuslavizki KH; Krisch B; Held-Feindt J; Henze E; Clausen M
    J Nucl Med; 2001 Sep; 42(9):1338-45. PubMed ID: 11535722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of [
    Bashir A; Vestergaard MB; Binderup T; Broholm H; Marner L; Ziebell M; Fugleholm K; Mathiesen T; Kjær A; Law I
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2577-2588. PubMed ID: 32170347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas.
    Nathoo N; Ugokwe K; Chang AS; Li L; Ross J; Suh JH; Vogelbaum MA; Barnett GH
    J Neurooncol; 2007 Jan; 81(2):167-74. PubMed ID: 16850106
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kowalski ES; Khairnar R; Gryaznov AA; Kesari V; Koroulakis A; Raghavan P; Chen W; Woodworth G; Mishra M
    Radiat Oncol; 2021 Aug; 16(1):151. PubMed ID: 34399805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
    Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
    Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of somatostatin receptor positron emission tomography imaging biomarkers for characterization of meningioma among incidental central nervous system lesions.
    Ensign SF; Agarwal M; Klanderman M; Badawy M; Halfdanarson TR; Johnson DR; Sonbol MB; Kendi AT
    Nucl Med Commun; 2023 Jul; 44(7):663-670. PubMed ID: 37158225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive differentiation of meningiomas from other brain tumours using combined 111Indium-octreotide/99mtechnetium-DTPA brain scintigraphy.
    Barth A; Haldemann AR; Reubi JC; Godoy N; Rösler H; Kinser JA; Seiler RW
    Acta Neurochir (Wien); 1996; 138(10):1179-85. PubMed ID: 8955437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
    Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J
    J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of 24-hour delayed imaging in somatostatin receptor scintigraphy for meningioma.
    Klutmann S; Bohuslavizki KH; Tietje N; Kröger S; Behnke A; Brenner W; Mester J; Henze E; Clausen M
    J Nucl Med; 1999 Aug; 40(8):1246-51. PubMed ID: 10450673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.